We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 14, 2020

Impact of Initial Treatment and Prognostic Factors on Post-Progression Survival in BRAF-Mutated Metastatic Melanoma

Journal of Translational Medicine


Additional Info

Journal of Translational Medicine
Impact of Initial Treatment and Prognostic Factors on Postprogression Survival in BRAF-Mutated Metastatic Melanoma Treated With Dacarbazine or Vemurafenib ± Cobimetinib: A Pooled Analysis of Four Clinical Trials
J Transl Med 2020 Aug 03;18(1)294, PA Ascierto, A Ribas, J Larkin, GA McArthur, KD Lewis, A Hauschild, KT Flaherty, E McKenna, Q Zhu, Y Mun, B Dréno

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading